International Stem Cell Corporation · OTC:ISCO

International Stem Cell — Investor Presentation (November 2019)

16 slides from International Stem Cell's investor presentation, Nov 27, 2019

  1. Slide 1: Cells for Therapy and Research

    Cells for Therapy and Research OTCQB ISCO www.internationalstemcell.com International Stem Cell Corporation bd@intlstemcell.com 5950 Priestly Drive 1-760-940-6383 Carlsbad CA 92008

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes certain statements, estimates and projections with respect to the anticipated future business and performance of the Company, which are collectively referred to as forward-looking statements. Forward-looking statements reflect various assumptions

  3. Slide 3: Cells for Therapy and Research

    Cells for Therapy and Research HLA-compatible stem cell platform Proprietary Robust pre-clinical Scalable pipeline addressing large unmet Ethical medical needs Neural stem cells Parkinson’s disease Stroke Commercially successful Liver cells biomedical business Crigler-Najjar syndrome α1-antitrypsin

  4. Slide 4: UniStemCell

    UniStemCell Unique stem cell platform technology Human parthenogenesis (unfertilized oocytes) PSC ESC iPS Adult Potential to Impractical Individual Individual Yes immune match each line is unique only only Fully proliferative/ Strong Varies Weak Economic source Strong Genes manipulated/ No No Yes No

  5. Slide 5: Intellectual Property

    Intellectual Property Freedom to operate in major jurisdictions Potential competitive advantages in EU 22 issued patents, 117 patent applications • Pluripotent cell development • Cell banking • Manufacturing methods • Cell differentiation • Treating diseases Numerous publications • Nature’s Scientif

  6. Slide 6: Broad Pipeline of Targets

    Broad Pipeline of Targets Clinical success unlocks significant value Pre- Indication IND Phase I/II clinical hpNSC Parkinson’s disease Ischemic stroke Spinal cord injury Metabolic liver diseases Retinal blindness Corneal blindness 6

  7. Slide 7: cGMP Manufacturing of NSC

    cGMP Manufacturing of NSC Highly optimized GMP process ‒ Virtually unlimited quantities of NSC ‒ Produces extremely pure cell populations ‒ Patented Differentiate Expand Thaw On-site QC Prep. Ideal product characteristics ‒ Cryopreservable ‒ Centralized manufacturing ‒ Easily scalable 7

  8. Slide 8: Parkinson's Disease

    Parkinson’s Disease # 2 Neurodegenerative disease Limited treatment options (symptomatic only) ‒ About 1 million people in US have PD ‒ Direct and indirect costs ~$25 billion ‒ Rarely diagnosed prior to 50 years of age ‒ Hallmark motor symptoms  Bradykinesia (slow movement)  Rigidity  Tremor ‒ Mo

  9. Slide 9: Summary of Non-clinical Studies

    Summary of Non-clinical Studies Proof of Principle Studies  6 month in 6-OHDA rodents  3 month in primates Dose Escalating Efficacy Study  Dose escalating study in 6-OHDA rodents Safety Studies  Acute toxicity in immune deficient rodents  9 month GLP pharm/tox., biodistribution and tumorigenici

  10. Slide 10: 12-Month MPTP-Lesioned Primate Data

    12-Month MPTP-Lesioned Primate Data Control Treatment 10

  11. Slide 11: 12-Month MPTP-Lesioned Primate Data

    12-Month MPTP-Lesioned Primate Data Transplanted Cells Integrate Dopamine Fiber Innervation Control Treatment 11

  12. Slide 12: 12-Month MPTP-Lesioned Primate Data

    12-Month MPTP-Lesioned Primate Data Dopamine levels post mortem Stable Parkscores and Healthy Behavior for duration of the study Functional activity demonstrated in disease model primates 9/1/2015 12

  13. Slide 13: Safety: 9-months GLP study

    Safety: 9-months GLP study Necropsy Biodistribution Tissue Finding Analysis Organs Analyzed Human cells detected Cervical lymph node Normal Salivary gland Normal Liver Not detected Thyroid w/ parathyroid Normal Kidney Not detected Esophagus, Trachea, Normal Heart Not detected Larynx, Tongue Diaphrag

  14. Slide 14: Phase 1 Clinical Trial – 2H 2015

    Phase 1 Clinical Trial – 2H 2015 12 month single arm dose escalating study ‒ Doses based on primate data ‒ 12 subjects with idiopathic Parkinson’s disease ‒ UPDRS < 49 in off-phase ‒ Stable on medications Primary endpoints: ‒ Safety  No worsening of symptoms  Brain lesions (MRI) ‒ Efficacy  Impro

  15. Slide 15: Prior Clinical Trials

    Prior Clinical Trials Freed, C. Transplantation of embryonic Olanow, C. W., et al. A double-blind controlled trial dopamine neurons for severe Parkinson's of bilateral fetal nigral transplantation in disease. N Engl J Med 344(10):710-719; Parkinson's disease. Annals of Neurology 54:403- 2001. 414; 2

  16. Slide 16: 2015/2016 Milestones

    2015/2016 Milestones Program 2H 2015 1H 2016 2H 2016 Phase I/IIa: • 6 months • Full clinical • Patient clinical data Parkinson’s disease enrollment data • US IND • Dosing (Phase II) • Animal • License Ophthalmology studies w/Rohto • New • New extra • Medical specialty strength Line products products

International Stem Cell — Investor Presentation (November 2019) on 6ix